United Kingdom Early Detection Initiative will generate the first UK cohort of individuals with new-onset #diabetes, designed specifically with the intention of facilitating earlier detection of #PancreaticCancer UK-EDI for Pancreatic Cancer bmjopen.bmj.com/content/12/10/…

BMG turning it purple on #worldpancreaticCancerday #EarlyDiagnosisSavesLives UK-EDI for Pancreatic Cancer Pancreatic Cancer Action @NIHRCRN_nwcoast

On World Pancreatic Cancer Day we are proud to be leading research into the earlier diagnosis of pancreatic cancer in those with new onset diabetes funded by Cancer Research UK Pancreatic Cancer UK. If you are a clinician able to help us in this task please get in touch by the email above.

Great The Pancreatic Society of Great Britain & Ireland conference in Leeds. If you would like to join the UK-EDI cohort study, or have diabetetology or GP network colleagues who can help please get in touch. Together we can make early detection a possibility.

First UK-EDI for Pancreatic Cancer research site opened in Wales Swansea Bay NHS each step taken is a step closer to #earlydetection

Congratulations to UK-EDI post- doc Lucy Oldfield for receiving an award at the Inst of Systems, Molecular & Integrative Biology away day. Lucy presented her research on strategies towards #earlydetection of #pancreaticcancer

A very happy retirement to David C Whitcomb MD PhD! A true giant in the field of #pancreatitis Discoverer of the cationic trypsinogen gene mutation in hereditary pancreatitis. Always kind and supportive to others.

Have you heard about type 3c diabetes? It can affect people with #PancreaticCancer. A lot of information about diabetes is about type 1 and type 2. But type 3c is different and is treated differently. Read our info to find out more this #DiabetesWeeK 👉 bit.ly/3J9TnHQ

UK-EDI for Pancreatic Cancer Clinical fellow @MStott88 presenting lessons learnt so far on UK-EDI for Pancreatic Cancer at #EDxConf23

UK-EDI for Pancreatic Cancer Chief investigator recent interview with Pancreatic Cancer Europe (PCE)

Excellent discussions and networking at the annual TRANSPAN meeting in Santiago, where Eithne Costello leads Working Group 1 TRANSPAN COST Action Science and Innovation at Cancer Research UK #pancreaticcancer #earlydetection

Great talk ⁦Irena Stefanova⁩ at the #EPC2024 ⁦TRANSPAN COST Action⁩ session. Presenting outputs of our ⁦UK-EDI for Pancreatic Cancer⁩ cost-benefit analysis for biomarker-driven early detection of #PancreaticCancer in new-onset diabetes ⁦Science and Innovation at Cancer Research UK⁩ ⁦⁦Molecular & Clinical Cancer Medicine (MCCM)⁩

That’s a wrap! What a fantastic 56th meeting of the European Pancreatic Club. Great to be here with some of the ⁦University of Liverpool⁩ #PancreaticCancer research team and to network with our international colleagues both old and new! #EPC2024 #CancerResearch

It was great spending some time with the wonderful team Pancreatic Cancer UK yesterday. Talking about the steps we are talking towards earlier detection of #PancreaticCancer

Members of the Molecular & Clinical Cancer Medicine (MCCM) Costello lab stand together with the #PancreaticCancer community on #WorldPancreaticCancerDay

Dr Lucy Oldfield is a researcher at University of Liverpool based in Molecular & Clinical Cancer Medicine (MCCM) who works closely with UK-EDI for Pancreatic Cancer promoting awareness of early detection of pancreatic cancer and Race for Life Cancer Research UK facebook.com/share/p/1F7AiY…

The UK-EDI for Pancreatic Cancer study is recruiting participants over 50 years old who have recently been diagnosed with type 2 diabetes, this study is open Gateshead Health NHS Foundation Trust . See info below if you are interested in taking part.

The UK-EDI for Pancreatic Cancer study is recruiting participants in Liverpool. Please find our contacts below. If you are out of our area but you would like to participate, please go to our website to find the nearest study site to you. NHS University Hospitals of Liverpool Group R&I

Combining a type-3c diabetes biomarker followed by a cancer-specific biomarker test may be more cost-effective than using either test alone for pancreatic ductal adenocarcinoma screening in patients with new-onset diabetes. ja.ma/47eMMXR